The innate immune system provides the first line of defence against foreign microbes and
particulate materials. Engineered nanoparticles can interact with the immune system in …

Nanomedicine involves the use of nanoparticles for therapeutic and diagnostic purposes.
During the past two decades, a growing number of nanomedicines have received regulatory …

When nanoparticles are intravenously injected into the body, complement proteins deposit
on the surface of nanoparticles in a process called opsonization. These proteins prime the …

Polymeric-micelle carrier systems have emerged as a novel drug-carrier system and have
been actively studied for anticancer drug targeting. In contrast, toxicological and …

The interactions between nanoparticles and macromolecules in the blood plasma dictate the
biocompatibility and efficacy of nanotherapeutics. Accordingly, the properties of …

Nanoparticle-based anticancer medications were first approved for cancer treatment almost
2 decades ago. Patients benefit from these approaches because of the targeted-drug …

The prevalence of neurological/neurodegenerative diseases, such as Alzheimer's disease is
known to be increasing due to an aging population and is anticipated to further grow in the …

Progress in drug delivery to the ear has been achieved over the last few years. This review
illustrates the main mechanisms of controlled drug release and the resulting geometry-and …

Notwithstanding rapid advances of nanotechnology in diagnostic imaging and drug delivery,
the engineered nanocarriers still exhibit substantial lack of hemocompatibility. Thus, when …

Considering the multifaceted protective and homeostatic roles of the complement system,
many consequences arise when drug carriers, and particulate pharmaceutical formulations …